| Ricardo C Alessio, MD | |
|
1101 W University Drive, Rochester, MI 48307-1831 | |
| (248) 652-5000 | |
| (248) 652-5605 |
| Full Name | Ricardo C Alessio |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 44 Years |
| Location | 1101 W University Drive, Rochester, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003868969 | NPI | - | NPPES |
| 0822338 | Other | MI | BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 043706 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension Providence - Crittenton Hospital Medical Center | Rochester, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Michigan Diagnostic Pathologists Pllc | 9739253279 | 8 |
News Archive
Levels of the Smad7 protein may predict therapeutic response in patients with prostate cancer according to research published by investigators at the Uppsala Branch of the Ludwig Institute for Cancer Research (LICR).
A new scientific statement issued today by the American Heart Association underscores the commonalities between cardiovascular disease and breast cancer among women, and it calls for more focus on research and specialized treatment where the diseases overlap.
Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., today announced that the New Drug Submission (NDS) for Lurasidone HCl, for the treatment of adult patients with schizophrenia has been accepted for review by Health Canada. The NDS was submitted to Health Canada in June 2011 and will receive a standard review.
Critical Outcome Technologies Inc. announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.
› Verified 2 days ago
| Entity Name | Michigan Diagnostic Pathologists Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578734281 PECOS PAC ID: 9739253279 Enrollment ID: O20080801000275 |
News Archive
Levels of the Smad7 protein may predict therapeutic response in patients with prostate cancer according to research published by investigators at the Uppsala Branch of the Ludwig Institute for Cancer Research (LICR).
A new scientific statement issued today by the American Heart Association underscores the commonalities between cardiovascular disease and breast cancer among women, and it calls for more focus on research and specialized treatment where the diseases overlap.
Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., today announced that the New Drug Submission (NDS) for Lurasidone HCl, for the treatment of adult patients with schizophrenia has been accepted for review by Health Canada. The NDS was submitted to Health Canada in June 2011 and will receive a standard review.
Critical Outcome Technologies Inc. announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ricardo C Alessio, MD Po Box 80275, Rochester Hills, MI 48308-0275 Ph: (248) 652-5000 | Ricardo C Alessio, MD 1101 W University Drive, Rochester, MI 48307-1831 Ph: (248) 652-5000 |
News Archive
Levels of the Smad7 protein may predict therapeutic response in patients with prostate cancer according to research published by investigators at the Uppsala Branch of the Ludwig Institute for Cancer Research (LICR).
A new scientific statement issued today by the American Heart Association underscores the commonalities between cardiovascular disease and breast cancer among women, and it calls for more focus on research and specialized treatment where the diseases overlap.
Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., today announced that the New Drug Submission (NDS) for Lurasidone HCl, for the treatment of adult patients with schizophrenia has been accepted for review by Health Canada. The NDS was submitted to Health Canada in June 2011 and will receive a standard review.
Critical Outcome Technologies Inc. announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.
› Verified 2 days ago
Dr. Glenn Allen Chamulak, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 1101 W University Dr, Department Of Pathology, Rochester, MI 48307 Phone: 248-652-5264 Fax: 248-652-5065 | |
David L Klionsky, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 1101 W University Drive, Rochester, MI 48307 Phone: 248-652-5000 Fax: 248-652-5605 | |
Michael Moon, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 1101 W University Drive, Rochester, MI 48307 Phone: 248-652-5000 Fax: 248-652-5605 | |
Dr. Stephanie Yoon Akins, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 414s Main St 207a, Rochester, MI 48307 Phone: 734-751-7721 Fax: 248-412-5305 |